Australia: Beach Energy given approval to drill Artisan-1 well in Otway Basin
14 Jan 2021
Artisan-1 exploration well in the Otway Basin.
Beach Energy proposes to drill a single exploration well (with the option to suspend and develop pending reservoir analysis) in Commonwealth waters of the Otway Basin approx. 32 km off Victoria’s south-west coast. The proposed Artisan-1 well location is at a water depth of approx. 71 m.
The operational area for the drilling program has been defined as a 2 km radius around the well location. The 2 km radius encompasses both the outer extent of mooring equipment on the seabed, and the 500 m petroleum safety zone.
Cepheid Gets Health Canada License For Four-in-one Rapid Molecular Diagnostic Test
WASHINGTON (dpa-AFX) - Cepheid, a unit of Danaher Corp. (DHR), said Thursday that it has received a medical device license from Health Canada for Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample.
The test is now available in Canada and can be used in laboratories and at the point of care.
Cepheid noted that the four-in-one test is designed for use on any of the company s almost 30,000 GeneXpert Systems placed worldwide, with results delivered in approximately 36 minutes.
BW Energy and the National Petroleum Corporation of Namibia (NAMCOR) have signed a Farm-In and Carry Agreement. The agreement increases BW Kudu’s working interest in the Kudu license offshore Namibia from 56% to 95%. NAMCOR will retain the remaining 5% working interest.
14 gennaio 2021 11:08
Fonte: Adnkronos
#salute-e-benessere
MILAN, Italy and HONG KONG, Jan. 14, 2021 /PRNewswire/ NTC, an international R&D focused pharmaceutical company headquartered in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agreement for exclusive license and distribution rights of NTC014, innovative fixed combination of a quinolone antibiotic and a NSAID in eye drops. Zhaoke will market NTC014 in the People s Republic of China, Hong Kong, Macau, Taiwan, ASEAN countries, and South Korea.
NTC014 aims to provide physicians with a rational treatment for moderate-severe bacterial conjunctivitis, a common eye infection. Actual treatment is mainly based on antibiotics combined/or not with steroids with no clear time window of administration. NTC014 is a first in class eye drop solution combining an antibiotic highly effective on the bacteria most
Activity on the Norwegian continental shelf last year remained at a high level, despite the ongoing pandemic. The year has been characterised by high production and significant investments in developments and projects on the fields.